Lang Peter, Mueller Ingo, Greil Johann, Bader Peter, Schumm Michael, Pfeiffer Matthias, Hoelle Walter, Klingebiel Thomas, Heinzelmann Frank, Belka Claus, Schlegel Paul G, Kremens Bernhard, Woessmann Wilhelm, Handgretinger Rupert
Department of Pediatric Oncology, University Children's Hospital, Eberhard Karl's University, Tübingen, Hoppe Seyler Strasse 1, 72076 Tübingen, Germany.
Blood Cells Mol Dis. 2008 Jan-Feb;40(1):33-9. doi: 10.1016/j.bcmd.2007.06.027. Epub 2007 Sep 19.
Graft failure is a life-threatening complication after transplantation of hematopoietic stem cells. We report a cohort of 11 pediatric patients with leukemias (n=8) and severe aplastic anemia (n=3) who experienced graft rejection after myeloablative transplantation from mismatched related donors (n=6) or after cord blood or matched unrelated donor transplantation (n=5). In the latter, the original donor was not available anymore. All patients were re-transplanted with CD34(+) selected or CD3/CD19 depleted stem cells from a second, haploidentical donor. Median time span from diagnosis of rejection to second transplant was 9 days. Reconditioning regimens comprised total lymphoid irradiation, thiotepa, fludarabine, ATG/OKT3 and were well tolerated. A median number of 23.5x10(6)/kg stem cells with 95,000/kg residual T-cells were infused. Sustained engraftment of neutrophiles/platelets and complete donor chimerism was achieved in all patients (ANC>500/microl: 9 (11-32) days). No GvHD>grade II was observed. 8/11 patients are disease free (median follow up 1.9 years; 1 year-EFS=72%). Causes of death were: pneumonitis, infection, relapse. Thus, haploidentical transplantation represents a realistic option to rescue patients with graft failure within a short time span, for whom a second donation from the original donor is not available. The use of different donors may contribute to avoid a second rejection.
移植物失败是造血干细胞移植后一种危及生命的并发症。我们报告了一组11例儿科患者,其中8例患有白血病,3例患有重型再生障碍性贫血,他们在接受来自不匹配相关供者的清髓性移植(6例)或脐血或匹配无关供者移植(5例)后发生了移植物排斥。在后一种情况下,原供者已无法再次提供。所有患者均接受了来自第二位单倍体相合供者的经CD34(+)选择或CD3/CD19去除的干细胞再次移植。从排斥诊断到第二次移植的中位时间间隔为9天。预处理方案包括全身淋巴照射、噻替派、氟达拉滨、抗胸腺细胞球蛋白/OKT3,且耐受性良好。输注的干细胞中位数为23.5×10(6)/kg,残余T细胞为95,000/kg。所有患者均实现了中性粒细胞/血小板的持续植入和完全供者嵌合(中性粒细胞绝对计数>500/μl:9(11 - 32)天)。未观察到>Ⅱ级的移植物抗宿主病。11例患者中有8例无病生存(中位随访1.9年;1年无事件生存率=72%)。死亡原因包括:肺炎、感染、复发。因此,单倍体相合移植是在短时间内挽救移植物失败患者的一种切实可行的选择,对于这些患者,原供者无法再次捐献。使用不同的供者可能有助于避免再次排斥。